Primary Care Diabetes
Volume 3, Issue 1 , Pages 5-15 , February 2009

Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications

  • Mehrul Hasnain

      Affiliations

    • Department of Psychiatry, Western Regional Integrated Health Authority, Sir Thomas Roddick Hospital, Stephenville, Newfoundland, Canada
    • Corresponding Author InformationCorresponding author at: Sir Thomas Roddick Hospital, 142 Minnesota Drive, Stephenville, Newfoundland A2N 2V6, Canada. Tel.: +1 709 643 1973; fax: +1 709 643 7911.
    • ,
  • W. Victor R. Vieweg

      Affiliations

    • Psychiatry Services, Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, VA, United States
    • Medical Services, Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, VA, United States
    • Department of Psychiatry, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA, United States
    • Department of Medicine, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA, United States
    • ,
  • Sonja K. Fredrickson

      Affiliations

    • Medical Services, Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, VA, United States
    • Department of Medicine, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA, United States
    • ,
  • Mary Beatty-Brooks

      Affiliations

    • Medical Media, Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, VA, United States
    • ,
  • Antony Fernandez

      Affiliations

    • Psychiatry Services, Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, VA, United States
    • Department of Psychiatry, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA, United States
    • ,
  • Anand K. Pandurangi

      Affiliations

    • Department of Psychiatry, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA, United States

Received 26 June 2008 ,Revised 23 October 2008 ,Accepted 24 October 2008.

References 

  1. Grant BF, Hasin DS, Chou SP, Stinson FS, Dawson DA. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch. Gen. Psychiatry. 2004;61:1107–1115
  2. Hagg S, Lindblom Y, Mjorndal T, Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int. Clin. Psychopharmacol. 2006;21:93–98
  3. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 2005;80:19–32
  4. Muck-Seler D, Pivac N, Jakovljevic M, Brzovic Z. Platelet serotonin, plasma cortisol, and dexamethasone suppression test in schizophrenic patients. Biol. Psychiatry. 1999;45:1433–1439
  5. Saari KM, Lindeman SM, Viilo KM, Isohanni MK, Jarvelin MR, Lauren LH, et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J. Clin. Psychiatry. 2005;66:559–563
  6. van Winkel R, De Hert M, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar. Disord. 2008;10:342–348
  7. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol. Med. 1999;29:697–701
  8. Compton MT, Daumit GL, Druss BG. Cigarette smoking and overweight/obesity among individuals with serious mental illnesses: a preventive perspective. Harv. Rev. Psychiatry. 2006;14:212–222
  9. Bellivier F. Schizophrenia, antipsychotics and diabetes: genetic aspects. Eur. Psychiatry. 2005;20(Suppl. 4):S335–S339
  10. Gough SC, O’Donovan MC. Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?. J. Psychopharmacol. 2005;19:47–55
  11. Tsang TM, Huang JT, Holmes E, Bahn S. Metabolic profiling of plasma from discordant schizophrenia twins: correlation between lipid signals and global functioning in female schizophrenia patients. J. Proteome Res. 2006;5:756–760
  12. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can. J. Psychiatry. 2006;51:480–491
  13. Yumru M, Savas HA, Kurt E, Kaya MC, Selek S, Savas E, et al. Atypical antipsychotics related metabolic syndrome in bipolar patients. J. Affect. Disord. 2007;98:247–252
  14. Le Noury J, Khan A, Harris M, Wong W, Williams D, Roberts T, et al. The incidence and prevalence of diabetes in patients with serious mental illness in North West Wales: two cohorts, 1875–1924 & 1994–2006 compared. BMC Psychiatry. 2008;8:67
  15. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J. Clin. Psychiatry. 2007;68(Suppl. 4):8–13
  16. Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Can. J. Psychiatry. 2006;51:492–501
  17. Barnett AH, Mackin P, Chaudhry I, Farooqi A, Gadsby R, Heald A, et al. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J. Psychopharmacol. 2007;21:357–373
  18. Barnes TR, Paton C, Cavanagh MR, Hancock E, Taylor DM. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr. Bull. 2007;33:1397–1403
  19. Jennex A, Gardner DM. Monitoring and management of metabolic risk factors in outpatients taking antipsychotic drugs: a controlled study. Can. J. Psychiatry. 2008;53:34–42
  20. Morrato EH, Newcomer JW, Allen RR, Valuck RJ. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. J. Clin. Psychiatry. 2008;69:316–322
  21. Mackin P, Bishop DR, Watkinson HM. A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients. BMC Psychiatry. 2007;7:28
  22. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  23. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler. Thromb. Vasc. Biol. 2004;24:e13–e18
  24. Kahn R. Metabolic syndrome—what is the clinical usefulness?. Lancet. 2008;371:1892–1893
  25. Sattar N, McConnachie A, Shaper AG, Blauw GJ, Buckley BM, de Craen AJ, et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet. 2008;371:1927–1935
  26. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–2752
  27. Spina E, Cavallaro R. The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia. Exp. Opin. Drug Saf. 2007;6:651–662
  28. Taylor DM, McAskill R. Atypical antipsychotics and weight gain—a systematic review. Acta Psychiatr. Scand. 2000;101:416–432
  29. Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Saf. 2006;29:303–319
  30. Leadbetter R, Shutty M, Pavalonis D, Vieweg V, Higgins P, Downs M. Clozapine-induced weight gain: prevalence and clinical relevance. Am. J. Psychiatry. 1992;149:68–72
  31. Conley RR, Kelly DL. Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects. Isr. J. Psychiatry Relat. Sci. 2005;42:51–60
  32. Haddad P. Weight change with atypical antipsychotics in the treatment of schizophrenia. J. Psychopharmacol. 2005;19:16–27
  33. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr. Res. 2004;70:1–17
  34. Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl.). 2006;189:259–266
  35. Kinon BJ, Lipkovich I, Edwards SB, Adams DH, scher-Svanum H, Siris SG. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J. Clin. Psychopharmacol. 2006;26:157–162
  36. Perez-Iglesias R, Crespo-Facorro B, Amado JA, Garcia-Unzueta MT, Ramirez-Bonilla ML, Gonzalez-Blanch C, et al. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J. Clin. Psychiatry. 2007;68:1733–1740
  37. Rettenbacher MA, Ebenbichler C, Hofer A, Kemmler G, Baumgartner S, Edlinger M, et al. Early changes of plasma lipids during treatment with atypical antipsychotics. Int. Clin. Psychopharmacol. 2006;21:369–372
  38. Spurling RD, Lamberti JS, Olsen D, Tu X, Tang W. Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review. J. Clin. Psychiatry. 2007;68:406–409
  39. Su KP, Wu PL, Pariante CM. A crossover study on lipid and weight changes associated with olanzapine and risperidone. Psychopharmacology (Berl.). 2005;183:383–386
  40. Wu RR, Zhao JP, Liu ZN, Zhai JG, Guo XF, Guo WB, et al. Effects of typical and atypical antipsychotics on glucose–insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl.). 2006;186:572–578
  41. de Leon J, Susce MT, Johnson M, Hardin M, Pointer L, Ruano G, et al. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr. Res. 2007;92:95–102
  42. Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev. 2007;13:137–177
  43. Birkenaes AB, Birkeland KI, Engh JA, Faerden A, Jonsdottir H, Ringen PA, et al. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J. Clin. Psychopharmacol. 2008;28:132–137
  44. Duncan E, Dunlop BW, Boshoven W, Woolson SL, Hamer RM, Phillips LS. Relative risk of glucose elevation during antipsychotic exposure in a Veterans Administration population. Int. Clin. Psychopharmacol. 2007;22:1–11
  45. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch. Gen. Psychiatry. 2005;62:19–28
  46. Henderson DC, Copeland PM, Borba CP, Daley TB, Nguyen DD, Cagliero E, et al. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J. Clin. Psychiatry. 2006;67:789–797
  47. Peuskens J, De HM, Mortimer A. Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. Int. Clin. Psychopharmacol. 2007;22:145–152
  48. DuMouchel W, Fram D, Yang X, Mahmoud RA, Grogg AL, Engelhart L, et al. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968–2004). Ann. Clin. Psychiatry. 2008;20:21–31
  49. Lambert BL, Cunningham FE, Miller DR, Dalack GW, Hur K. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. Am. J. Epidemiol. 2006;164:672–681
  50. Gianfrancesco F, Wang RH, Nasrallah HA. The influence of study design on the results of pharmacoepidemiologic studies of diabetes risk with antipsychotic therapy. Ann. Clin. Psychiatry. 2006;18:9–17
  51. Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J. Clin. Psychiatry. 2002;63:920–930
  52. Ramaswamy K, Masand PS, Nasrallah HA. Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies. Ann. Clin. Psychiatry. 2006;18:183–194
  53. Holt RI, Peveler RC. Antipsychotic drugs and diabetes—an application of the Austin Bradford Hill criteria. Diabetologia. 2006;49:1467–1476
  54. Cohen D, Stolk RP, Grobbee DE, Gispen-de Wied CC. Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders. Diabetes Care. 2006;29:786–791
  55. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am. J. Psychiatry. 2002;159:561–566
  56. Cohen D, Dekker JJ, Peen J, Gispen-de Wied CC. Prevalence of diabetes mellitus in chronic schizophrenic inpatients in relation to long-term antipsychotic treatment. Eur. Neuropsychopharmacol. 2006;16:187–194
  57. Etminan M, Streiner DL, Rochon PA. Exploring the association between atypical neuroleptic agents and diabetes mellitus in older adults. Pharmacotherapy. 2003;23:1411–1415
  58. Hammerman A, Dreiher J, Klang SH, Munitz H, Cohen AD, Goldfracht M. Antipsychotics and diabetes: an age-related association. Ann. Pharmacother. 2008;42:1316–1322
  59. Saddichha S, Manjunatha N, Ameen S, Akhtar S. Metabolic syndrome in first episode schizophrenia—a randomized double-blind controlled, short-term prospective study. Schizophr. Res. 2008;101:266–272
  60. L’Italien GJ, Casey DE, Kan HJ, Carson WH, Marcus RN. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. J. Clin. Psychiatry. 2007;68:1510–1516
  61. De Hert M, Schreurs V, Sweers K, Van ED, Hanssens L, Sinko S, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr. Res. 2008;101:295–303
  62. Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr. Res. 2008;101:273–286
  63. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol. Psychiatry. 2008;13:27–35
  64. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH. From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc. Natl. Acad. Sci. U.S.A. 2007;104:3456–3459
  65. Reynolds GP, Hill MJ, Kirk SL. The 5-HT2C receptor and antipsychoticinduced weight gain—mechanisms and genetics. J. Psychopharmacol. 2006;20:15–18
  66. Sentissi O, Epelbaum J, Olie JP, Poirier MF. Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schizophr. Bull. 2008;34:1189–1199
  67. Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab. Pharmacokinet. 2005;20:368–378
  68. Hasnain M, Vieweg WVR. Acute effects of newer antipsychotic drugs on glucose metabolism. Am. J. Med. 2008;121:e17
  69. Vestri HS, Maianu L, Moellering DR, Garvey WT. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology. 2007;32:765–772
  70. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin. Endocrinol. (Oxf.). 2006;64:355–365
  71. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596–601
  72. Vieweg WV, Sood AB, Pandurangi A, Silverman JJ. Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain?. Acta Psychiatr. Scand. 2005;111:177–184
  73. Hasnain M, Vieweg WV, Hettema JM, Colton D, Fernandez A, Pandurangi AK. The risk of overweight in children and adolescents with major mental illness. South Med. J. 2008;101:367–372
  74. Vieweg WV, Levy JR, Fredrickson SK, Chipkin SR, Beatty-Brooks M, Fernandez A, et al. Psychotropic drug considerations in depressed patients with metabolic disturbances. Am. J. Med. 2008;121:647–655
  75. Henderson DC, Cagliero E, Copeland PM, Louie PM, Borba CP, Fan X, et al. Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics. J. Clin. Psychiatry. 2007;68:533–541
  76. Roberts L, Roalfe A, Wilson S, Lester H. Physical health care of patients with schizophrenia in primary care: a comparative study. Fam. Pract. 2007;24:34–40
  77. Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr. Res. 2006;86:15–22
  78. Desai MM, Rosenheck RA, Druss BG, Perlin JB. Mental disorders and quality of diabetes care in the veterans health administration. Am. J. Psychiatry. 2002;159:1584–1590
  79. Frayne SM, Halanych JH, Miller DR, Wang F, Lin H, Pogach L, et al. Disparities in diabetes care: impact of mental illness. Arch. Intern. Med. 2005;165:2631–2638
  80. Derry S, Moore RA. Atypical antipsychotics in bipolar disorder: systematic review of randomised trials. BMC Psychiatry. 2007;7:40
  81. Motlova L, Spaniel F, Hoschl C, Balon R. Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders?. Ann. Clin. Psychiatry. 2007;19:133–143
  82. Elmslie JL, Mann JI, Silverstone JT, Williams SM, Romans SE. Determinants of overweight and obesity in patients with bipolar disorder. J. Clin. Psychiatry. 2001;62:486–491
  83. McCreadie RG. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br. J. Psychiatry. 2003;183:534–539
  84. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, et al. Physical health monitoring of patients with schizophrenia. Am. J. Psychiatry. 2004;161:1334–1349
  85. Meyer JM, Pandina G, Bossie CA, Turkoz I, Greenspan A. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin. Ther. 2005;27:1930–1941
  86. Garman PM, Ried LD, Bengtson MA, Hsu C, McConkey JR. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia. J. Am. Pharm. Assoc. (2003). 2007;47:373–378
  87. Montes JM, Rodriguez JL, Balbo E, Sopelana P, Martin E, Soto JA, et al. Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2007;31:383–388
  88. De Hert M, Hanssens L, van WR, Wampers M, Van ED, Scheen A, et al. A case series: evaluation of the metabolic safety of aripiprazole. Schizophr. Bull. 2007;33:823–830
  89. Weiden PJ, Buckley PF. Reducing the burden of side effects during long-term antipsychotic therapy: the role of “switching” medications. J. Clin. Psychiatry. 2007;68(Suppl. 6):14–23
  90. Baptista T, ElFakih Y, Uzcategui E, Sandia I, Talamo E, raujo de BE, et al. Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs. 2008;22:477–495
  91. Faulkner G, Cohn TA. Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications. Can. J. Psychiatry. 2006;51:502–511
  92. Tschoner A, Engl J, Laimer M, Kaser S, Rettenbacher M, Fleischhacker WW, et al. Metabolic side effects of antipsychotic medication. Int. J. Clin. Pract. 2007;61:1356–1370
  93. Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am. J. Psychiatry. 2008;165:352–358
  94. Chen CH, Chiu CC, Huang MC, Wu TH, Liu HC, Lu ML. Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2008;32:925–931
  95. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am. J. Psychiatry. 2006;163:2072–2079
  96. Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA. 2008;299:185–193
  97. Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am. J. Psychiatry. 2002;159:655–657
  98. Ratner RE. An update on the Diabetes Prevention Program. Endocr. Pract. 2006;12(Suppl. 1):20–24
  99. Irons BK, Greene RS, Mazzolini TA, Edwards KL, Sleeper RB. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus. Pharmacotherapy. 2006;26:168–181
  100. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 1998;15:539–553
  101. Reaven GM. The metabolic syndrome: is this diagnosis necessary?. Am. J. Clin. Nutr. 2006;83:1237–1247
  102. The IDF consensus worldwide definition of the metabolic syndrome, 2006, http://www.idf.org/webdata/docs/MetS_def_update2006.pdf (Ref type: electronic citation).

PII: S1751-9918(08)00108-3

doi: 10.1016/j.pcd.2008.10.005

Primary Care Diabetes
Volume 3, Issue 1 , Pages 5-15 , February 2009

Article Tools

* Image Usage & Resolution